

# New Medicines Decisions for April 2025

Nivolumab in combination with ipilimumab				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
NCMAG121	Nivolumab in combination with ipilimumab for the neoadjuvant treatment of resectable stage III melanoma	Available in line with local or regional guidance	24/04/2025	22/10/2025
<b>Other Decision Specified :</b> National Cancer Medicines Advisory Group (NCMAG) Programme				
<b>Web Link :</b> <a href="https://www.healthcareimprovementscotland.scot/wp-content/uploads/2025/04/NCMAG121-Nivolumab-in-combination-with-ipilimumab-Advice-Document-v1.0-1.pdf">https://www.healthcareimprovementscotland.scot/wp-content/uploads/2025/04/NCMAG121-Nivolumab-in-combination-with-ipilimumab-Advice-Document-v1.0-1.pdf</a>				
Pembrolizumab				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
NCMAG122	Pembrolizumab for the neoadjuvant treatment of stage IIIB to IIID or oligometastatic resectable stage IV melanoma	Available in line with local or regional guidance	24/04/2025	22/10/2025
<b>Other Decision Specified :</b> National Cancer Medicines Advisory Group (NCMAG) Programme				
<b>Web Link :</b> <a href="https://www.healthcareimprovementscotland.scot/wp-content/uploads/2025/04/NCMAG122-Pembrolizumab-Advice-Document-v-1.0.pdf">https://www.healthcareimprovementscotland.scot/wp-content/uploads/2025/04/NCMAG122-Pembrolizumab-Advice-Document-v-1.0.pdf</a>				

futibatinib (Lytgobi®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2661	as monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	07/04/2025	17/06/2025
Other Decision Specified :				
Web Link : <a href="https://scottishmedicines.org.uk/media/9086/futibatinib-lytgobi-abb-final-march-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9086/futibatinib-lytgobi-abb-final-march-2025-for-website.pdf</a>				
bimekizumab (Bimzelx®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2698	for the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. SMC restriction: for use in adult patients with active moderate to severe HS for whom adalimumab is contraindicated or otherwise unsuitable, including those who have failed to respond or have lost response to prior adalimumab treatment.	Available in line with local or regional guidance	07/04/2025	22/10/2025
Other Decision Specified :				
Web Link : <a href="https://scottishmedicines.org.uk/media/9082/bimekizumab-bimzelx-final-march-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9082/bimekizumab-bimzelx-final-march-2025-for-website.pdf</a>				

elafibranor (Iqirvo®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2714	for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	07/04/2025	27/02/2026
Other Decision Specified :				
Web Link : <a href="https://scottishmedicines.org.uk/media/9084/elafibranor-iqirvo-final-march-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9084/elafibranor-iqirvo-final-march-2025-for-website.pdf</a>				
tebentafusp (Kimmtrak®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC274	as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.	Not routinely available as not recommended for use in NHS Scotland	07/04/2025	19/03/2025
Other Decision Specified :				
Web Link : <a href="https://scottishmedicines.org.uk/media/9088/tebentafusp-kimmtrak-resub-final-march-2025-amended-030425-for-website.pdf">https://scottishmedicines.org.uk/media/9088/tebentafusp-kimmtrak-resub-final-march-2025-amended-030425-for-website.pdf</a>				

# New Medicines Decisions for April 2025

<b>alectinib (Alecensa®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2749	as monotherapy as adjuvant treatment for adult patients with Stage IB (tumours $\geq$ 4 cm) to IIIA (7th edition of the UICC/AJCC-staging system) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) following complete tumour resection.	Available in line with local or regional guidance	07/04/2025	17/09/2025
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9081/alectinib-alecensa-final-march-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9081/alectinib-alecensa-final-march-2025-for-website.pdf</a>				
<b>eplontersen (Wainzua®)</b>				
<b>SMC Drug ID</b>	<b>Conditions</b>	<b>Decision</b>	<b>Date published on SMC Website</b>	<b>Date of decision / Expected date of decision</b>
SMC2755	for the treatment of hereditary transthyretin-mediated amyloidosis (ATTRv amyloidosis) in adult patients with Stage 1 and 2 polyneuropathy.	Routinely available from a specialist centre in another health board	07/04/2025	25/06/2025
<b>Other Decision Specified :</b>				
<b>Web Link :</b> <a href="https://scottishmedicines.org.uk/media/9085/eplontersen-wainzua-abb-final-march-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9085/eplontersen-wainzua-abb-final-march-2025-for-website.pdf</a>				

dapagliflozin (Forxiga®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2763	<p>in adults for the treatment of chronic kidney disease (CKD). SMC restriction: in patients having individually optimised standard care (including angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, unless these are contraindicated or not tolerated), and either, at the start of treatment:</p> <ul style="list-style-type: none"> <li>• an estimated glomerular filtration rate (eGFR) of 20 mL/min/1.73m<sup>2</sup> up to 45 mL/min/1.73m<sup>2</sup>, or</li> <li>• an eGFR of 45 mL/min/1.73m<sup>2</sup> up to 90 mL/min/1.73m<sup>2</sup> and either: <ul style="list-style-type: none"> <li>o A urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more, or</li> <li>o Type 2 Diabetes Mellitus (T2DM).</li> </ul> </li> </ul>	Available in line with local or regional guidance	09/04/2025	17/06/2025
Other Decision Specified :				
Web Link : <a href="https://scottishmedicines.org.uk/media/9083/dapagliflozin-forxiga-abb-final-march-2025-for-website.pdf">https://scottishmedicines.org.uk/media/9083/dapagliflozin-forxiga-abb-final-march-2025-for-website.pdf</a>				